UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Explore a practical plan to stop overspending, reset your numbers, and build a sustainable budget that fits your income and goals.
17,082 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
A public clash between a legendary director and a veteran actor isn’t just drama. It’s a window into how money, reput...
Two tech giants just reported blowout results. This guide breaks down what the numbers mean and how to decide which g...
Oil prices surged to a peak near $119 before pulling back, creating a volatile week for markets. Here are three takea...
As mortgage rates shift and originations evolve, loandepot (LDI) 2025 earnings will hinge on rate flow, loan mix, and...
As nephros (neph) 2025 earnings approach, investors weigh revenue growth, margins, and cash runway. This guide breaks...
Opendoor Technologies has shown dramatic swings from a penny-like floor to double digits—driven by hype rather than f...
Archer Aviation is venturing into urban air mobility with electric VTOL aircraft. This piece analyzes the case for bu...
Micron Technology expands in Taiwan by acquiring Powerchip's P5 site, boosting DRAM and HBM capacity and setting up a...
Discover four durable dividend growth stocks that can help your portfolio compound over time. Learn why these picks f...
As June 30 approaches, questions swirl around Tesla stock. This guide weighs the real catalysts, risks, and practical...
Choosing between VNQ and RWX boils down to cost, geography, and how you want to shape your real estate exposure. This...